| Document |
Document Title |
|
WO/2024/059790A1 |
The present application relates to an integrated one vector system for identifying a genome modifying enzyme, e.g., from a large library. The one-vector system integrates the components for enzyme identification into a single vector to f...
|
|
WO/2024/059516A1 |
Disclosed herein are compositions and methods related to the fast and efficient generation of cDNA library from RNA. The method allows integration of the method in an automation adaptable system.
|
|
WO/2024/059618A2 |
Provided herein are recombinant nucleic acids that reduce expression of TGFBR1 and/or TGFBR2 and cells comprising such recombinant nucleic acids. Also provided are methods of making and using such cells.
|
|
WO/2024/058192A1 |
Provided is a novel antibody which may be used for the treatment of SARS-CoV-2. An antibody or an antigen-binding fragment thereof according to the present disclosure is an anti-CADM1 antibody or an antigen-binding fragment thereof, wh...
|
|
WO/2024/055429A1 |
Disclosed in the present invention are an SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus and the use thereof. The present invention uses an S protein or RBD of the SARS-COV-2 antigen polypeptide as an antigen. A tru...
|
|
WO/2024/059321A1 |
Compositions and methods enhancing a patient's immune response to an immune stimulatory composition are disclosed. In certain embodiments, the method includes administering a composition comprising a PHD pathway inhibitor and a vaccine t...
|
|
WO/2024/058178A1 |
The present invention provides a reagent that is for measuring an epidermal growth factor receptor tyrosine kinase activity and that contains: a modified polypeptide to which an acceptor and a donor inducing Förster resonance energy tra...
|
|
WO/2024/058589A1 |
The present invention relates to a chimeric antigen receptor (CAR) cell prepared using genetic scissor knock-in, and a use thereof, and more specifically to a method for preparing a single guide RNA (sgRNA) for TGF beta receptor 2 (TGFBR...
|
|
WO/2024/055108A1 |
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for prev...
|
|
WO/2024/059569A2 |
Provided herein are retroviral vector systems useful for producing universal pseudotyped retroviruses for cell and gene therapies. The vector systems include an envelope plasmid and a packaging plasmid, where at least one of these plasmi...
|
|
WO/2024/059494A1 |
Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD...
|
|
WO/2024/055376A1 |
A method for treating an adhesive in recycled pulp by means of a pectin lyase and a use. The pectin lyase PMGL-Ba is a pectinase capable of directly acting on highly methylated pectin to effectively cleave α-1,4 glycosidic bonds of poly...
|
|
WO/2024/058155A1 |
The present invention addresses the problem of providing a new method for simply and efficiently producing linear covalently closed DNA. Provided is a double stranded circular DNA vector, wherein the double stranded circular DNA vector...
|
|
WO/2024/006902A9 |
The present disclosure relates to a sustained release silica hydrogel composite comprising an anti-complement agent and methods of using same to treat ophthalmological conditions. The anti-complement agent may be an anti-C5 agent compris...
|
|
WO/2024/055941A1 |
Provided are methods of preparing a circular RNA, comprising providing a template DNA, wherein the template DNA comprises a sequence encoding a precursor RNA, in a reaction solution to allow synthesis of precursor RNA by in vitro transcr...
|
|
WO/2024/055627A1 |
The present application provides a primer-molecular beacon combination for molecular typing of a wild type and a mutant type of a monkey poxvirus and use thereof. The primer-molecular beacon combination comprises a primer pair and a mole...
|
|
WO/2023/056139A9 |
The present disclosure provides genome editing compositions comprising a ribonucleoprotein (RNP) complex comprising: i) a class 2 CRISPR-Cas effector polypeptide, or a nucleic acid comprising a nucleotide sequence encoding the class 2 CR...
|
|
WO/2024/058252A1 |
A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected fr...
|
|
WO/2024/056038A1 |
The present invention belongs to the field of genetic engineering and provides a modified CaPif1 helicase, a complex comprising the helicase, a construct comprising the helicase, a method for using the helicase or the complex or the cons...
|
|
WO/2024/059517A1 |
Described herein are CB5 polypeptides for the biosynthesis of oxygenated hydrocarbons in modified host cells.
|
|
WO/2024/056902A2 |
The disclosure features compositions and methods for the treatment of disorders associated with expression of wild-type or mutant Ataxin-2 (ATXN2) RNA transcripts, including disorders characterized by genes containing aberrantly expanded...
|
|
WO/2024/058198A1 |
Provided is a production method which is for induced pluripotent stem cells and by which induced pluripotent stem cells having high undifferentiation properties and differentiation potency are easily obtained. A production method for i...
|
|
WO/2024/055406A1 |
The present invention provides a soybean saponin-related KASP marker and use thereof, and belongs to the technical field of molecular breeding. The KASP marker comprises one or two of S07_43139773G/T and SO7_43139033A/G. The S07_43139773...
|
|
WO/2024/059197A1 |
The present disclosure relates to methods, compositions, and kits for providing cleaved, single-stranded nucleic acids. Such nucleic acids can be used to provide ladder compositions.
|
|
WO/2024/056898A1 |
The present invention relates to a genetically modified Clostridium acetobutylicum able to grow on lignocellulosic biomass, in which the cip-cel operon is overexpressed, the expression level of each gene of the cip-cel operon in the gene...
|
|
WO/2024/059811A2 |
Compounds, polypeptides, compositions, and nucleic acid molecules are provided herein that can be used, for example, to edit the genome of a cell, such as a human cell.
|
|
WO/2024/059165A1 |
The invention relates to methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, e.g., nonalcoholic steatohepatitis (NASH), ...
|
|
WO/2024/057315A1 |
The present invention relates to compositions and methods for producing target- specific therapeutic agents with improved properties, useful in oncolytic viro therapy, gene therapy, cell therapy and immunotherapy. Specifically, the inven...
|
|
WO/2023/230308A9 |
The present disclosure provides compounds of the formulae herein (e.g., Formulae (I) or (II)), and pharmaceutically acceptable salts thereof, which are degrader compounds of Quiescin Sulfhydryl Oxidase 1 (QSOX1) mRNA. The present disclos...
|
|
WO/2024/055273A1 |
Provided herein are a rabies mRNA vaccine and preparation and use thereof. Specifically provided herein is a rabies immunogen nucleic acid expression vector, which comprises sequentially from the 5' end to the 3' end: (a) a 5'-UTR elemen...
|
|
WO/2024/058300A1 |
The present invention relates to a composition for detecting the infection of viral hemorrhagic septicemia virus (VHSV), a kit comprising the composition, and a method for diagnosing the infection of VHSV using same. Specifically, the pr...
|
|
WO/2024/058111A1 |
The present invention provides a method or the like for efficiently screening candidate substances for a hexanal-odor suppressing material. A screening method according to the present invention comprises: adding a test substance and hexa...
|
|
WO/2024/059641A2 |
Provided herein are compositions and methods for modifying T cells.
|
|
WO/2024/058717A1 |
Described herein are lipase variants of a Rhizomucor Miehei Lipase. The lipase variants may be used to prepare medium to long chain N-acyl glcyines. The variants may have a parent sequence of SEQ ID NO: 3; and a D156 substitution and/or ...
|
|
WO/2024/056856A1 |
The present invention embraces systems, kits and compositions comprising two RNA molecules, wherein the first RNA molecule comprises an open reading frame encoding a functional RNA-dependent RNA polymerase (replicase) and wherein the sec...
|
|
WO/2024/056044A1 |
The present disclosure relates to genetically modified animals and methods for producing heavy-chain antibodies. In one aspect, the genetically modified non-human animal comprises a modified immunoglobulin heavy chain locus, wherein the ...
|
|
WO/2024/055272A1 |
Provided is an mRNA expression vector capable of efficiently expressing a target protein, the mRNA expression vector, sequentially from the 5' end to the 3' end, comprising: (a) a 5'-UTR element; (b) an open reading frame element encodin...
|
|
WO/2023/081299A9 |
The present disclosure provides a method for noninvasively diagnosing and staging a progressive chronic lung disease characterized by disease related lung dysfunction by deriving from a biological sample from a subject a purified enriche...
|
|
WO/2024/059881A2 |
Nucleic acid products are provided that modulate, in particular interfere with or inhibit AGT gene expression. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first n...
|
|
WO/2024/057333A1 |
The present disclosure relates to a process for preparing bio-products from biomass. The present disclosure relates to ecologically sustainable process for preparation of 2nd generation ethanol by hydrolysis of celluloses of ligno-cellul...
|
|
WO/2023/010046A9 |
Methods are described for cell-type mapping utilizing direct measurement of low-dimensional representation of single-cell transcriptomics with a supervised machine learning algorithm to spatially map cell types, bypassing the need to mea...
|
|
WO/2024/056027A1 |
The present invention provides use of an ldh gene-containing lactobacillus plantarum in preparing a product for relieving enteritis. The lactobacillus plantarum or plasmid involved in the present invention is an ldh gene-containing lacto...
|
|
WO/2024/059735A2 |
Provided are recombinant adeno-associated virus (rAAV) vectors, methods of treating an ocular condition, pharmaceutical compositions, and other compositions and methods, in which the rAAV vector comprises a polynucleotide encoding oxidor...
|
|
WO/2024/056905A1 |
The present invention relates to a vegan immunoassay for verifying a biologically active antigen, a device in which such an immunoassay is arranged, a kit having such a device, use of the immunoassay and a method for verifying a biologic...
|
|
WO/2024/059756A1 |
Heart failure WITH Preserved Ejection Fraction (HFpEF) effects approximately three million people in the United States.
|
|
WO/2024/059464A1 |
The invention provides recombinant DNA polynucleotides and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and s...
|
|
WO/2024/058234A1 |
The present invention provides human T cells lacking human leukocyte antigen (HLA) class I molecules and containing an exogenous ST6GALNAC6 gene, the T cells having the following characteristics (a) and/or (b): (a) being CD62L-positive a...
|
|
WO/2024/055928A1 |
An anti-monkeypox virus antibody or an antigen binding fragment thereof, and a reagent and kit for detecting monkeypox virus, which relate to the field of antibodies. The anti-monkeypox virus antibody comprises a heavy-chain complementar...
|
|
WO/2024/055123A1 |
Compositions, nucleic acids and polypeptides for treating and preventing infectious salmon anaemia (ISA) in finfish are provided. In one embodiment, a vaccine is provided comprising one or more nucleic acid molecules, optionally mRNA, en...
|
|
WO/2024/059824A2 |
Provided herein are recombinant nucleic acids that reduce expression of CD5, CBLB, CISH, DGKA, DGKZ, DNMT3A, MAP4K1, NR4A1, PTPN2, TET2, or ZC3H12A and cells comprising such recombinant nucleic acids. Also provided are methods of making ...
|
